Research programme: decoy oligonucleotide therapeutics - AnGes MG

Drug Profile

Research programme: decoy oligonucleotide therapeutics - AnGes MG

Alternative Names: NF-kappa-B/E2F decoy oligonucleotide; NF-kappa-B/Ets decoy oligonucleotide

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnGes MG
  • Developer AnGes MG; Osaka University
  • Class Oligonucleotides
  • Mechanism of Action E2F transcription factor inhibitors; Matrix metalloproteinase inhibitors; NF-kappa B inhibitors; Proto-oncogene-protein-c-ets inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Vascular disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Vascular-disorders in Japan (Parenteral)
  • 30 Nov 2011 Pharmacodynamics data from a preclinical study in Vascular disorders released by AnGes MG
  • 17 Nov 2008 Preclinical trials in Vascular disorders in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top